News Conference News AHA 2025 Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD Todd Neale November 13, 2025
News Conference News AHA 2022 Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI Yael L. Maxwell November 10, 2022
News Conference News AHA 2020 Latest Post-DES Drug Trial Tests Aspirin Monotherapy After 1 Month of DAPT Shelley Wood November 15, 2020
News Conference News AHA 2017 ‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18 Michael O'Riordan November 15, 2017
News Conference News AHA 2016 Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI Todd Neale November 14, 2016
News Conference News AHA 2015 DAPT Score Provides ‘Personalized Medicine’ Tool for Determining Whether to Extend Therapy Beyond 1 Year Yael L. Maxwell November 09, 2015
News Conference News AHA 2015 AHA 2015 Promises Appropriate PCI, Ticagrelor Tolerance, Outcomes With IVUS, and More Shelley Wood November 05, 2015
News Conference News AHA 2014 Biodegradable-Polymer DES Perform Well But Appear No Safer than Their Durable-Polymer Counterparts November 18, 2014
News Conference News AHA 2014 DAPT Study Shows Benefit of Long-Term Treatment After DES Implantation Yael L. Maxwell November 16, 2014
News Conference News AHA 2014 Long-Term Better than Short-Term Prasugrel After PES Stenting November 15, 2014
News Conference News AHA 2014 ITALIC Shows Noninferiority of 6-Month DAPT in Good Aspirin Responders Yael L. Maxwell November 15, 2014
News Conference News AHA 2014 ISAR-SAFE: Another Randomized Trial Finds 6 Months of DAPT as Good as 12 Months November 15, 2014